{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017028","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.900098+00:00","generated_at":"2026-06-22T00:44:09.819368+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GlycoMimetics reports Q3 2022 financials; FDA clears interim analysis for uproleselan Phase 3","bullets":["Cash $51.6M as of Sep 30, 2022 vs $90.3M at Dec 31, 2021; cash runway extended to end of 2023.","FDA cleared protocol amendment for interim utility analysis of uproleselan Phase 3 in relapsed/refractory AML.","Blinded pooled survival data show patients living longer than historically expected; DMC meeting by end Q1 2023.","Final survival events trigger projected around year-end 2023, later than originally anticipated.","R&D expenses decreased to $4.9M from $13.3M YoY due to Phase 3 enrollment completion."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017028","json":"https://secwatch.observer/filing/0001558370-22-017028.json","markdown":"https://secwatch.observer/filing/0001558370-22-017028.md","text":"https://secwatch.observer/filing/0001558370-22-017028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837022017028/0001558370-22-017028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837022017028/glyc-20221109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:44:09.819368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"693d8c948d6a6dfefb98375b7f0dbe3653baedfd","claim":"CRESCENT BIOPHARMA, INC. reported third quarter ended September 30, 2022 results: revenue There was no revenue recognized during the three months ended September 30, 2022.","evidence_excerpt":"On November 9, 2022, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837022017028/0001558370-22-017028-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"There was no revenue recognized during the three months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}